In Vivo Evidence in the Brain for Lithium Inhibition of Glycogen Synthase Kinase-3

There is considerable interest in the possibility that small-molecule glycogen synthase kinase-3 inhibitors may have utility in the treatment of bipolar disorder, since glycogen synthase kinase-3 is a target of lithium. Although the in vitro inhibition of glycogen synthase kinase-3 by lithium occurs with a Ki of 1–2 mM, the degree of inhibition of this enzyme in the mammalian brain at therapeutically relevant concentrations has not fully been established. The transcription factor β-catenin is an established marker of glycogen synthase kinase-3 inactivation because cytoplasmic levels are increased by inhibition of the enzyme. In this study, we measured β-catenin protein levels after treatment with therapeutically relevant doses of lithium, valproate, and carbamazepine. Western blot revealed that 9 days of treatment with lithium and valproate, but not carbamazepine, increased β-catenin protein levels in soluble fractions from the frontal cortex. The level of β-catenin in the particulate fraction, which is not directly regulated by glycogen synthase kinase-3, did not change with any of the three drugs. Furthermore, real-time PCR revealed that lithium significantly decreased β-catenin mRNA levels, which may represent compensation for an increase in β-catenin stability. These results strongly suggest that lithium significantly inhibits brain glycogen synthase kinase-3 in vivo at concentrations relevant for the treatment of bipolar disorder.

[1]  T. Hamamura,et al.  Carbamazepine Suppresses Methamphetamine-Induced Fos Expression in a Regionally Specific Manner in the Rat Brain , 2000, Neuropsychopharmacology.

[2]  I. Reynolds,et al.  Glutamate-induced increases in intracellular free Mg2+ in cultured cortical neurons , 1993, Neuron.

[3]  B. Hyman,et al.  Neonatal neuronal overexpression of glycogen synthase kinase-3β reduces brain size in transgenic mice , 2002, Neuroscience.

[4]  R. Belmaker,et al.  The mechanism of lithium action: state of the art, ten years later , 2001, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[5]  J. Perlman,et al.  Hypermagnesemia does not increase brain intracellular magnesium in newborn swine. , 2001, Pediatric neurology.

[6]  Ana Martínez,et al.  Inhibitors of glycogen synthase kinase-3: future therapy for unmet medical needs? , 2002 .

[7]  K. Kinzler,et al.  The molecular basis of Turcot's syndrome. , 1995, The New England journal of medicine.

[8]  H. Manji,et al.  Mood stabilizer psychopharmacology , 2002, Clinical Neuroscience Research.

[9]  T. Sugimura,et al.  Frequent mutations of the rat β‐catenin gene in colon cancers induced by methylazoxymethanol acetate plus 1‐hydroxyanthraquinone , 1999, Molecular carcinogenesis.

[10]  M. Wolter,et al.  Somatic mutations of WNT/wingless signaling pathway components in primitive neuroectodermal tumors , 2001, International journal of cancer.

[11]  C. A. Masuda,et al.  Phosphoglucomutase is an in vivo lithium target in yeast. , 2001, The Journal of biological chemistry.

[12]  Jon W. Johnson,et al.  Free intracellular Mg2+ concentration and inhibition of NMDA responses in cultured rat neurons , 2001, The Journal of physiology.

[13]  D. Jacobowitz,et al.  Lack of effect of chronic carbamazepine on brain somatostatin in the rat , 1987, Journal of Neural Transmission.

[14]  Mercedes Alonso,et al.  Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation , 2002, Medicinal research reviews.

[15]  R. Post,et al.  Carbamazepine and carbamazepine-10,11-epoxide inhibit amygdala-kindled seizures in the rat but do not block their development. , 1987, Clinical neuropharmacology.

[16]  R. Nusse,et al.  Mechanisms of Wnt signaling in development. , 1998, Annual review of cell and developmental biology.

[17]  M. Peifer,et al.  Wnt signaling in oncogenesis and embryogenesis--a look outside the nucleus. , 2000, Science.

[18]  H. Kato,et al.  Intracellular Mg2+ surge follows Ca2+ increase during depolarization in cultured neurons , 1999, Brain Research.

[19]  D. Chuang,et al.  Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Y. Yonekawa,et al.  APC mutations in sporadic medulloblastomas. , 2000, The American journal of pathology.

[21]  Husseini K. Manji,et al.  The Wnt Signaling Pathway in Bipolar Disorder , 2002, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[22]  J. Ponder,et al.  Definition of a metal-dependent/Li(+)-inhibited phosphomonoesterase protein family based upon a conserved three-dimensional core structure. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[23]  C. Geraldes,et al.  Comparison of Fluorescence, 31P NMR, and 7Li NMR Spectroscopic Methods for Investigating Li+/Mg2+ Competition for Biomolecules , 1999 .

[24]  F. McCormick,et al.  Differential Regulation of Glycogen Synthase Kinase 3β by Insulin and Wnt Signaling* , 2000, The Journal of Biological Chemistry.

[25]  James R. Woodgett,et al.  Lithium inhibits glycogen synthase kinase-3 activity and mimics Wingless signalling in intact cells , 1996, Current Biology.

[26]  P. Cohen,et al.  The renaissance of GSK3 , 2001, Nature Reviews Molecular Cell Biology.

[27]  C. Phiel,et al.  Molecular targets of lithium action. , 2003, Annual review of pharmacology and toxicology.

[28]  Xiaohua Li,et al.  Regulation of Akt and glycogen synthase kinase-3β phosphorylation by sodium valproate and lithium , 2002, Neuropharmacology.

[29]  R. Post,et al.  Chronic Carbamazepine Treatment Increases Brain Adenosine Receptors , 1985, Epilepsia.

[30]  P. Shaw,et al.  Glycogen synthase kinase-3β-mediated tau phosphorylation in cultured cell lines , 2003 .

[31]  D. Melton,et al.  A molecular mechanism for the effect of lithium on development. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[32]  J. Ávila,et al.  Lithium inhibits Alzheimer's disease‐like tau protein phosphorylation in neurons , 1997, FEBS letters.

[33]  S. Bustin.  Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. , 2000, Journal of molecular endocrinology.

[34]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[35]  H. Eldar-Finkelman,et al.  Glycogen synthase kinase 3: an emerging therapeutic target. , 2002, Trends in molecular medicine.

[36]  H. Manji,et al.  Lithium Activates the c‐Jun NH2‐Terminal Kinases In Vitro and in the CNS In Vivo , 1999, Journal of neurochemistry.

[37]  J. Markley,et al.  Enzyme-bound intermediates in the conversion of glucose 1-phosphate to glucose 6-phosphate by phosphoglucomutase. Phosphorus NMR studies. , 1984, Biochemistry.

[38]  James R. Woodgett,et al.  Judging a Protein by More Than Its Name: GSK-3 , 2001, Science's STKE.

[39]  A. M. Arias,et al.  Wnt signalling: a theme with nuclear variations , 2001, BioEssays : news and reviews in molecular, cellular and developmental biology.

[40]  W. Elyaman,et al.  In vivo activation and nuclear translocation of phosphorylated glycogen synthase kinase‐3β in neuronal apoptosis: links to tau phosphorylation , 2002, The European journal of neuroscience.

[41]  B. Doble,et al.  GSK-3: tricks of the trade for a multi-tasking kinase , 2003, Journal of Cell Science.

[42]  Anjen Chenn,et al.  Regulation of Cerebral Cortical Size by Control of Cell Cycle Exit in Neural Precursors , 2002, Science.

[43]  Dianqing Wu,et al.  Suppression of Glycogen Synthase Kinase Activity Is Not Sufficient for Leukemia Enhancer Factor-1 Activation* , 1999, The Journal of Biological Chemistry.

[44]  P. Cohen,et al.  Specificity and mechanism of action of some commonly used protein kinase inhibitors. , 2000, The Biochemical journal.

[45]  Philip Cohen,et al.  GSK3 takes centre stage more than 20 years after its discovery. , 2001 .

[46]  C. Geraldes,et al.  Competition between Li+ and Mg2+ in neuroblastoma SH-SY5Y cells: a fluorescence and 31P NMR study. , 1999, Biophysical journal.

[47]  P. S. Klein,et al.  Lithium and valproic acid: parallels and contrasts in diverse signaling contexts. , 2002, Pharmacology & therapeutics.

[48]  R. Jope,et al.  The multifaceted roles of glycogen synthase kinase 3β in cellular signaling , 2001, Progress in Neurobiology.

[49]  S. Fujita,et al.  Inhibition of Protein Phosphatase 2A Overrides Tau Protein Kinase I/Glycogen Synthase Kinase 3β and Cyclin-dependent Kinase 5 Inhibition and Results in Tau Hyperphosphorylation in the Hippocampus of Starved Mouse* , 2001, The Journal of Biological Chemistry.

[50]  Marty W. Mayo,et al.  WNT-1 Signaling Inhibits Apoptosis by Activating β-Catenin/T Cell Factor–Mediated Transcription , 2001, The Journal of cell biology.

[51]  C. W. Scott,et al.  Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3beta in cellular and animal models of neuronal degeneration. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[52]  W. Ray,et al.  The binding of lithium and of anionic metabolites to phosphoglucomutase. , 1978, Biochimica et biophysica acta.

[53]  A. Harwood,et al.  Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. , 2001, Biochemical and biophysical research communications.

[54]  H. Manji,et al.  The Mood Stabilizer Valproic Acid Activates Mitogen-activated Protein Kinases and Promotes Neurite Growth* , 2001, The Journal of Biological Chemistry.